Drug Profile
Recombinant interleukin 11 - Kerun Biopharmaceutical
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Kerun Biopharmaceutical
- Class Chemoprotectants; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin-11 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Thrombocytopenia
Most Recent Events
- 13 Jun 2016 Registered for Thrombocytopenia (Chemotherapy-induced) in China (unspecified route) before June 2016
- 31 Dec 1999 Kerun Biopharmaceutical receives approval for conducting clinical trials for recombinant interleukin-11 protein in thrombocytopenia in China (Kerun Biopharmaceutical website) before December 1999